Clinical Trials on Recurrent Non Small Cell Lung Cancer in Chile

Total 110 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
AstraZeneca

Completed

A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients (KINDLE)

Non-small-cell Lung Cancer (NSCLC)

Mexico, Peru, Argentina, Taiwan, India, Thailand, Colombia, Uruguay, Chile, Dominican Republic
AstraZeneca

Completed

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer (EARLY-EGFR)

Non-small Cell Lung Cancer

Vietnam, Turkey, Philippines, Thailand, Egypt, Singapore, India, Peru, Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Kuwait, Mexico
Eli Lilly and Company

Completed

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

Argentina, Brazil, Chile, Mexico
Sanofi

Completed

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

Non-small Cell Lung Cancer

France, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
International Atomic Energy Agency

Completed

Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy

Non Small Cell Lung Cancer

Chile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
Agennix

Completed

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Lung Cancer

United States, Canada, Chile
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, Brazil, Korea, Republic of, Spain, Argentina, United States, Costa Rica, Chile, Latvia, Finland, Italy, Poland
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain, Greece, Poland, Canada, Lithuania, Norway
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
mAbxience Research S.L.

Completed

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

Non-small Cell Lung Cancer

Philippines, Hungary, Chile, Mexico, Spain, Serbia, Malaysia, Brazil, Bulgaria, Georgia, Greece, India, Lebanon, Oman, Russian Federation, Thailand, Turkey, Ukraine
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

Non-Squamous Non-Small Cell Lung Cancer

United States, Italy, Canada, Austria, Finland, France, Greece, Korea, Republic of, Panama, Portugal, Spain, Turkey, United Kingdom, Taiwan, Brazil, Germany, Poland, Chile, Guatemala, Russian Federation, Switzerland, Thailand, Ukraine, Serb... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Germany, Thailand, Brazil, Japan, Hong Kong, Austria, Greece, Switzerland, Netherlands, Romania, Hungary, Italy, Chile, Taiwan, Poland, Canada, Argentina, Turkey
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

Non-small Cell Lung Cancer

United States, Canada, Italy, Spain, Malaysia, Taiwan, Turkey, Australia, Germany, Netherlands, Singapore, Argentina, Austria, Czechia, Switzerland, United Kingdom, Korea, Republic of, Thailand, France, Japan, Lebanon, Greece, Hong... and more
Novartis Pharmaceuticals

Terminated

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2)

Non-Small-Cell Lung

Germany, Spain, Belgium, Canada, Netherlands, Italy, Taiwan, Argentina, Australia, Israel, Japan, Lebanon, France, Poland, United States, Jordan, Korea, Republic of, China, Brazil, Czechia, Greece, Russian Federation, Denmark, Hungary, ... and more
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

Israel, Taiwan, United States, Australia, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

Metastatic Non-small Cell Lung Cancer

Poland, China, United States, Argentina, Brazil, Chile, France, Guatemala, Hungary, Japan, Romania, South Africa, Spain, Taiwan, Thailand, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Metastatic Non-Small Cell Lung Cancer

Poland, United States, Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Spain, Taiwan, Thailand, Turkey, United Kingdom
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Sweden, Belgium, Denmark, China, Austria, United Kingdom, Germany and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Bulgaria, Turkey, Argentina, Belgium, Greece, Mala... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Nereus Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Cancer

United States, Australia, India, Chile, Brazil, Argentina
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Nonsquamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Chile, China, France, Germany, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, United Kingdom
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Non-small-cell Lung Carcinoma | Lung Carcinomas, Non-Small-Cell

Spain, Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan, Lebanon, Malaysia, Mexico, Philippines, Poland, Romania, Russian Federation, Taiwan, Thailand, Turkey, Ukraine
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
Bristol-Myers Squibb

Completed

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Belgium, Germany, Israel, Poland, Spain, Turkey, Australia, Chile, France
GlaxoSmithKline

Active, not recruiting

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

Argentina, Korea, Republic of, Taiwan, France, Spain, Italy, United States, Germany, Romania, Poland, Brazil, Chile
Dizal Pharmaceuticals

Active, not recruiting

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Non-Small Cell Lung Cancer

Korea, Republic of, Spain, United States, France, Taiwan, Italy, China, Argentina, Australia, Malaysia, Canada, Japan, Chile
Hoffmann-La Roche

Active, not recruiting

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Spain, Argentina, China, France, Turkey, Brazil, Korea, Republic of, Mexico, Chile, Guatemala, Peru, Thailand, Costa Rica, United Kingdom, New Zealand, Hungary, Latvia, Russian Federation, South Africa, Ukraine, Italy, Greece, Poland
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Spain, Thailand, Italy, Sweden, Turkey, Colombia, Costa Rica, Hong Kong, Poland, Chile, United Kingdom, New... and more
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)

Non-Small Cell Lung Cancer

Italy, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Japan, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
AstraZeneca

Active, not recruiting

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

Non-Small Cell Lung Cancer

Belgium, Italy, Spain, United States, Poland, India, Taiwan, Thailand, Vietnam, Canada, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation, China, Austria, Chile, Netherlands, Bulg... and more
GlaxoSmithKline

Active, not recruiting

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (ZEAL-1L)

Lung Cancer, Non-Small Cell

Argentina, France, Spain, Italy, Belgium, Korea, Republic of, United States, Mexico, Hungary, Sweden, Turkey, Ireland, Greece, Russian Federation, Germany, Netherlands, Bulgaria, Romania, Brazil, United Kingdom, Poland, Australia, C... and more
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, United States, Korea, Republic of, Canada, Poland, Taiwan, Spain, Lebanon, Malaysia, Turkey, Italy, India, Norway, Croatia, Thailand, Hong Kong, Brazil, Greece, Colombia, Bulgaria, Jordan, Romania, Serbia, Slovenia, Denmark, Vietnam, Estoni... and more

Clinical Trials on Recurrent Non Small Cell Lung Cancer in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations